A
46.00
-0.36 (-0.78%)
| Penutupan Terdahulu | 46.36 |
| Buka | 47.35 |
| Jumlah Dagangan | 3,599,250 |
| Purata Dagangan (3B) | 1,367,835 |
| Modal Pasaran | 3,667,009,536 |
| Harga / Buku (P/B) | 3.41 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -3.75 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.34% |
| Nisbah Semasa (MRQ) | 16.80 |
| Aliran Tunai Operasi (OCF TTM) | -262.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -177.47 M |
| Pulangan Atas Aset (ROA TTM) | -18.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Akero Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
0.9
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.88 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.38% |
| % Dimiliki oleh Institusi | 109.28% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 78.00 (Citigroup, 69.57%) | Beli |
| Median | 75.00 (63.04%) | |
| Rendah | 64.00 (B of A Securities, 39.13%) | Beli |
| Purata | 72.33 (57.24%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 43.85 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 27 May 2025 | 64.00 (39.13%) | Beli | 46.00 |
| Citigroup | 13 May 2025 | 78.00 (69.57%) | Beli | 40.01 |
| HC Wainwright & Co. | 03 Mar 2025 | 75.00 (63.04%) | Beli | 45.54 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |